201 related articles for article (PubMed ID: 27472081)
41. The upregulation of zinc finger protein 670 and prostaglandin D2 synthase in proliferative vitreoretinopathy.
Kuo HK; Chen YH; Huang F; Wu YC; Shiea J; Wu PC
Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):205-13. PubMed ID: 25940552
[TBL] [Abstract][Full Text] [Related]
42. Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy.
Abu El-Asrar AM; Struyf S; Kangave D; Geboes K; Van Damme J
Eur Cytokine Netw; 2006 Sep; 17(3):155-65. PubMed ID: 17194635
[TBL] [Abstract][Full Text] [Related]
43. Intravitreal Steroids for the Prevention of PVR After Surgery for Retinal Detachment.
Gagliano C; Toro MD; Avitabile T; Stella S; Uva MG
Curr Pharm Des; 2015; 21(32):4698-702. PubMed ID: 26350528
[TBL] [Abstract][Full Text] [Related]
44. Growth factors outside the PDGF family drive experimental PVR.
Lei H; Velez G; Hovland P; Hirose T; Gilbertson D; Kazlauskas A
Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3394-403. PubMed ID: 19324843
[TBL] [Abstract][Full Text] [Related]
45. Vitreous vascular endothelial growth factor concentrations in proliferative diabetic retinopathy versus proliferative vitreoretinopathy.
Citirik M; Kabatas EU; Batman C; Akin KO; Kabatas N
Ophthalmic Res; 2012; 47(1):7-12. PubMed ID: 21691136
[TBL] [Abstract][Full Text] [Related]
46. The effect of tranilast on experimental proliferative vitreoretinopathy.
Ito S; Sakamoto T; Tahara Y; Goto Y; Akazawa K; Ishibashi T; Inomata H
Graefes Arch Clin Exp Ophthalmol; 1999 Aug; 237(8):691-6. PubMed ID: 10459620
[TBL] [Abstract][Full Text] [Related]
47. [Proliferative vitreoretinopathy: pathophysiology and clinical diagnosis].
Rouberol F; Chiquet C
J Fr Ophtalmol; 2014 Sep; 37(7):557-65. PubMed ID: 24997864
[TBL] [Abstract][Full Text] [Related]
48. Therapeutic effect of periocular corticosteroids in experimental proliferative vitreoretinopathy.
Rubsamen PE; Cousins SW
Retina; 1997; 17(1):44-50. PubMed ID: 9051842
[TBL] [Abstract][Full Text] [Related]
49. Retinoic acid in silicone and silicone-fluorosilicone copolymer oils in a rabbit model of proliferative vitreoretinopathy.
Nakagawa M; Refojo MF; Marin JF; Doi M; Tolentino FI
Invest Ophthalmol Vis Sci; 1995 Nov; 36(12):2388-95. PubMed ID: 7591628
[TBL] [Abstract][Full Text] [Related]
50. Activation of neural progenitor cells in human eyes with proliferative vitreoretinopathy.
Johnsen EO; Frøen RC; Albert R; Omdal BK; Sarang Z; Berta A; Nicolaissen B; Petrovski G; Moe MC
Exp Eye Res; 2012 May; 98():28-36. PubMed ID: 22465407
[TBL] [Abstract][Full Text] [Related]
51. Intercellular adhesion molecule-1 in proliferative vitreoretinopathy.
Limb GA; Chignell AH; Cole CJ; Green WT; Webster L; Hollifield RD; Dumonde DC
Invest Ophthalmol Vis Sci; 1997 Apr; 38(5):1043-8. PubMed ID: 9113001
[TBL] [Abstract][Full Text] [Related]
52. Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumors.
Emerling BM; Hurov JB; Poulogiannis G; Tsukazawa KS; Choo-Wing R; Wulf GM; Bell EL; Shim HS; Lamia KA; Rameh LE; Bellinger G; Sasaki AT; Asara JM; Yuan X; Bullock A; Denicola GM; Song J; Brown V; Signoretti S; Cantley LC
Cell; 2013 Nov; 155(4):844-57. PubMed ID: 24209622
[TBL] [Abstract][Full Text] [Related]
53. A Novel Role of IL13Rα2 in the Pathogenesis of Proliferative Vitreoretinopathy.
Qi H; Dong L; Fang D; Chen L; Wang Y; Fan N; Mao X; Wu W; Yan X; Zhang G; Zhang S; Lei H
Front Med (Lausanne); 2022; 9():831436. PubMed ID: 35770008
[TBL] [Abstract][Full Text] [Related]
54. Proliferative vitreoretinopathy in the Swine-a new model.
Umazume K; Barak Y; McDonald K; Liu L; Kaplan HJ; Tamiya S
Invest Ophthalmol Vis Sci; 2012 Jul; 53(8):4910-6. PubMed ID: 22729438
[TBL] [Abstract][Full Text] [Related]
55. Doxycycline Ameliorates the Severity of Experimental Proliferative Vitreoretinopathy in Mice.
Chen SH; Lin YJ; Wang LC; Tsai HY; Yang CH; Teng YT; Hsu SM
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769100
[TBL] [Abstract][Full Text] [Related]
56. The Effect of Anti-Autotaxin Aptamers on the Development of Proliferative Vitreoretinopathy.
Hanazaki H; Yokota H; Yamagami S; Nakamura Y; Nagaoka T
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958909
[TBL] [Abstract][Full Text] [Related]
57. Pirfenidone inhibits post-traumatic proliferative vitreoretinopathy.
Khanum BNMK; Guha R; Sur VP; Nandi S; Basak SK; Konar A; Hazra S
Eye (Lond); 2017 Sep; 31(9):1317-1328. PubMed ID: 28304388
[TBL] [Abstract][Full Text] [Related]
58. A novel function of p53: a gatekeeper of retinal detachment.
Lei H; Rheaume MA; Cui J; Mukai S; Maberley D; Samad A; Matsubara J; Kazlauskas A
Am J Pathol; 2012 Sep; 181(3):866-74. PubMed ID: 22901751
[TBL] [Abstract][Full Text] [Related]
59. Tenascin-C levels in the vitreous of patients with proliferative vitreoretinopathy.
Mitamura Y; Takeuchi S; Ohtsuka K; Matsuda A; Yamamoto T; Yamamoto S; Hiraiwa N; Kusakabe M
Ophthalmologica; 2003; 217(6):422-5. PubMed ID: 14573976
[TBL] [Abstract][Full Text] [Related]
60. [Experimental morphological study of posttraumatic proliferative vitreoretinopathy prevention by cell adhesion peptide Arg-Gly-Asp-Ser].
Khoroshilova-Maslova IP; Babizhaev MA; Kiseleva OA; Ilatovskaia LV
Vestn Oftalmol; 1997; 113(4):27-31. PubMed ID: 9381638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
